[go: up one dir, main page]

MX2022012110A - Sistemas crispr clase ii tipo ii. - Google Patents

Sistemas crispr clase ii tipo ii.

Info

Publication number
MX2022012110A
MX2022012110A MX2022012110A MX2022012110A MX2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A MX 2022012110 A MX2022012110 A MX 2022012110A
Authority
MX
Mexico
Prior art keywords
class
type
crispr systems
enzymes
crispr
Prior art date
Application number
MX2022012110A
Other languages
English (en)
Inventor
Christopher Brown
Brian Thomas
Audra Devoto
Cristina Butterfield
Lisa Alexander
Daniela S A Goltsman
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of MX2022012110A publication Critical patent/MX2022012110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Confectionery (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)

Abstract

La presente invención proporciona enzimas de endonucleasa así como métodos para usar estas enzimas o variantes de las mismas.
MX2022012110A 2020-03-31 2021-03-30 Sistemas crispr clase ii tipo ii. MX2022012110A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003159P 2020-03-31 2020-03-31
US202063116149P 2020-11-19 2020-11-19
PCT/US2021/024945 WO2021202568A1 (en) 2020-03-31 2021-03-30 Class ii, type ii crispr systems

Publications (1)

Publication Number Publication Date
MX2022012110A true MX2022012110A (es) 2022-10-18

Family

ID=77929138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012110A MX2022012110A (es) 2020-03-31 2021-03-30 Sistemas crispr clase ii tipo ii.

Country Status (10)

Country Link
US (2) US11946039B2 (es)
EP (2) EP4127156B1 (es)
JP (2) JP7546689B2 (es)
KR (2) KR102794727B1 (es)
CN (1) CN116096877A (es)
AU (1) AU2021248800A1 (es)
CA (1) CA3177051A1 (es)
GB (1) GB2608292B (es)
MX (1) MX2022012110A (es)
WO (1) WO2021202568A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CN113728097A (zh) * 2019-02-14 2021-11-30 宏基因组学知识产权技术有限责任公司 具有ruvc结构域的酶
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021146641A1 (en) * 2020-01-17 2021-07-22 The Broad Institute, Inc. Small type ii-d cas proteins and methods of use thereof
KR102794727B1 (ko) 2020-03-31 2025-04-11 메타지노미, 인크. 클래스 ii, 유형 ii crispr 시스템
AU2021339819A1 (en) * 2020-09-11 2023-05-25 Metagenomi, Inc. Base editing enzymes
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
EP4426826A4 (en) 2021-11-05 2025-08-20 Metagenomi Inc BASIC EDITION ENZYMES
AU2022396533A1 (en) * 2021-11-24 2024-05-02 Metagenomi, Inc. Endonuclease systems
EP4437095A1 (en) * 2021-11-24 2024-10-02 Metagenomi, Inc. Endonuclease systems
ES2970263B2 (es) * 2022-10-21 2024-10-11 Univ Alicante PROTEINA ENDONUCLEASA Cas9 Y SISTEMA CRISPR-Cas ASOCIADO
EP4680287A1 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024206759A1 (en) * 2023-03-31 2024-10-03 Arbor Biotechnologies, Inc. Crispr nuclease polypeptides and gene editing systems comprising such
CN121241133A (zh) * 2023-03-31 2025-12-30 阿伯生物技术公司 Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统
WO2024206825A2 (en) * 2023-03-31 2024-10-03 Aera Therapeutics, Inc. Modified iscb nucleases, modified guide rnas, and uses thereof
WO2024233366A2 (en) * 2023-05-05 2024-11-14 Aera Therapeutics, Inc. Modified cas9-iid nucleases and uses thereof
WO2024243456A2 (en) * 2023-05-23 2024-11-28 Metagenomi, Inc. Endonuclease systems
WO2025007044A1 (en) * 2023-06-28 2025-01-02 The University Of Chicago Methods and compositions comprising iscb variants
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025054425A1 (en) * 2023-09-08 2025-03-13 Arbor Biotechnologies, Inc. Reverse transcription-mediated gene editing systems and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN108913676B (zh) 2012-12-06 2023-11-03 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控
ES2576128T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones para la manipulación de secuencias con dominios funcionales
DK2898075T3 (en) 2012-12-12 2016-06-27 Broad Inst Inc CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
WO2016186953A1 (en) 2015-05-15 2016-11-24 Pioneer Hi Bred International Inc Guide rna/cas endonuclease systems
EP3303634B1 (en) 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
IL284808B (en) 2015-06-18 2022-07-01 Broad Inst Inc Mutations in the crispr enzyme that reduce unintended effects
US20190161742A1 (en) 2016-03-11 2019-05-30 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
MX2019003678A (es) * 2016-09-30 2020-08-13 Univ California Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
US11840694B2 (en) 2016-10-17 2023-12-12 Nanyang Technological University Truncated CRISPR-Cas proteins for DNA targeting
WO2018209712A1 (en) 2017-05-19 2018-11-22 Tsinghua University Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna
SG11201906297QA (en) 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
CA3058584A1 (en) 2017-03-30 2018-10-04 Kyoto University Method for inducing exon skipping by genome editing
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
SG11202007382TA (en) 2018-02-15 2020-08-28 Sigma Aldrich Co Llc Engineered cas9 systems for eukaryotic genome modification
EP3755792A4 (en) 2018-02-23 2021-12-08 Pioneer Hi-Bred International, Inc. NEW CASE ORTHOLOGISTS9
WO2020055941A1 (en) 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
US20220220460A1 (en) 2019-02-14 2022-07-14 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CN113728097A (zh) * 2019-02-14 2021-11-30 宏基因组学知识产权技术有限责任公司 具有ruvc结构域的酶
EP3924482A4 (en) * 2019-02-14 2023-04-05 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220403357A1 (en) * 2019-11-12 2022-12-22 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
KR102794727B1 (ko) 2020-03-31 2025-04-11 메타지노미, 인크. 클래스 ii, 유형 ii crispr 시스템
EP4127155A1 (en) * 2020-03-31 2023-02-08 Metagenomi, Inc. Class ii, type ii crispr systems
WO2021226369A1 (en) 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
JP7778087B2 (ja) 2020-05-08 2025-12-01 メタゲノミ，インク． Ｒｕｖｃドメインを有する酵素
CN116867897A (zh) * 2020-09-11 2023-10-10 宏基因组学公司 碱基编辑酶
AU2021339819A1 (en) * 2020-09-11 2023-05-25 Metagenomi, Inc. Base editing enzymes
CA3193961A1 (en) 2020-10-23 2022-04-28 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof

Also Published As

Publication number Publication date
GB2608292B (en) 2024-02-14
KR20220161383A (ko) 2022-12-06
US20240309356A1 (en) 2024-09-19
JP2024178181A (ja) 2024-12-24
JP2023519953A (ja) 2023-05-15
GB2608292A (en) 2022-12-28
US11946039B2 (en) 2024-04-02
EP4127156A1 (en) 2023-02-08
EP4127156B1 (en) 2025-09-10
AU2021248800A1 (en) 2022-10-13
CN116096877A (zh) 2023-05-09
WO2021202568A1 (en) 2021-10-07
JP7785139B2 (ja) 2025-12-12
KR20250051161A (ko) 2025-04-16
US20230051396A1 (en) 2023-02-16
CA3177051A1 (en) 2021-10-07
GB202211839D0 (en) 2022-09-28
EP4127156A4 (en) 2024-03-27
JP7546689B2 (ja) 2024-09-06
EP4632066A3 (en) 2025-12-24
EP4632066A2 (en) 2025-10-15
EP4127156C0 (en) 2025-09-10
KR102794727B1 (ko) 2025-04-11

Similar Documents

Publication Publication Date Title
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
GB2605340A8 (en) Base editing enzymes
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
MX2022014067A (es) Enzimas con dominios ruvc.
TN2023000250A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
WO2021127283A3 (en) Irak degraders and uses thereof
WO2020236972A3 (en) Non-classi engineered crispr-cas polynucleotide targeting system
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2022011039A (es) Sistemas crispr clase ii tipo v.
SA519402400B1 (ar) تركيبات وطرق لعلاج أمراض الهيموجلوبين
PH12019502171A1 (en) Composition and methods for immunooncology
WO2019117673A3 (ko) 신규 폴리펩타이드 및 이를 이용한 imp 생산방법
MY189774A (en) Atropine-containing aqueous composition
WO2020003006A3 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
MX2021001070A (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
WO2022232638A3 (en) Enzymes with ruvc domains
WO2018146557A3 (en) Long double-stranded rna for rna interference
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
GB2615901A8 (en) Base editing enzymes
WO2023081762A3 (en) Serine recombinases
WO2022266456A3 (en) Proteases for beer haze reduction
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
WO2020237122A3 (en) Cleaning systems for additive manufacturing apparatuses and methods for using the same
MX2023014356A (es) Sistemas crispr de clase ii, tipo v.